Vorinostat MSD for cutaneous T-cell lymphoma. MSD withdraws marketing application

Excerpts from the EMEA press release (dated 17th February) on the withdrawal of the marketing application for Vorinostat MSD: The European Medicines Agency (EMEA) has been formally notified by Merck Sharp & Dohme Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Vorinostat MSD (vorinostat), 100 mg hard […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos